EGFR and non-small cell lung carcinoma: This suggests that co-inhibition of EGFR and SHP-2 is an effective approach to overcome EGFRT790M mutation-acquired resistance to EGFR tyrosine kinase inhibitors, thus supporting SHP-2 expression as a new biomarker in NSCLC treatment (206).